Clik here to view.
Neurocrine CEO Kevin Gorman to retire after 32-year run; Bluebird picks up...
Kevin Gorman After more than three decades at Neurocrine, CEO Kevin Gorman will retire later this year, handing the reins of the $13 billion neuroscience drugmaker over to Kyle Gano, a longtime...
View ArticleIonis outlines Phase 3 data for rare disease drug, preps for another...
Ionis outlined full Phase 3 results for its rare disease drug donidalorsen on Friday, prepping for a potential FDA submission by the end of the year. The study is Ionis’ third Phase 3 win in the last...
View ArticleClik here to view.
Adaptimmune taps Galapagos to decentralize manufacturing of solid tumor T...
Adaptimmune Therapeutics and Galapagos have formed an alliance to manufacture a clinical-stage solid cancer asset in a decentralized way. Thad Huston At the center of the deal is Adamtimmune’s T cell...
View ArticleClik here to view.
#ASCO24: Gilead presents more data on failed Trodelvy lung cancer study
CHICAGO — Researchers on Friday afternoon pulled back the curtain on Gilead’s previously announced Phase 3 failure in certain forms of non-small cell lung cancer. Gilead’s TROP2 antibody-drug conjugate...
View ArticleClik here to view.
#ASCO24: Novartis' new CML treatment tops older drugs, including Gleevec, in...
CHICAGO — Novartis said its chronic myeloid leukemia drug Scemblix was better than its own first-generation blockbuster medicine and an investigator’s choice of second-generation treatments made by...
View ArticleNovartis shares updated data for BTK inhibitor; Astellas resubmits BLA for...
Plus, news about Valar Labs, Pharming Group and Day One Pharmaceuticals: Novartis outlines one-year data for BTK inhibitor: The drug, called remibrutinib, demonstrated symptom improvements up to one...
View ArticleFDA approves Moderna's RSV vaccine, marking its second commercial product
Moderna on Friday secured a long-awaited but expected approval for its RSV vaccine, giving the biotech its first FDA approval for a non-Covid-19 product and kickstarting what’s now a three-way race...
View ArticleJoe Jimenez and Mark Fishman target $400M for third fund after leaving Novartis
Former Novartis CEO Joe Jimenez and research leader Mark Fishman are fundraising again for their life sciences firm Aditum Bio, which in-licenses translational-stage drugs and sets up individual...
View ArticleClik here to view.
'Invisible hand' of inherited genetics can drive cancer risk, new study suggests
For almost as long as scientists have understood how genetic mutations can drive the growth of cancers, they’ve also believed that most of those mutations are acquired over the course of a person’s...
View ArticleDrugmakers to Maryland affordability board: Capping list prices may not help...
Drugmakers are pushing back against Maryland’s Prescription Drug Affordability Board and its list of six medicines that will be reviewed for potential price caps. The board is conducting studies of six...
View ArticleCHMP recommends 14 new approvals, seven label expansions
The European Medicines Agency’s human medicines committee recommended 14 new drugs for approval this week, including Pfizer’s gene therapy for hemophilia B. The approval recommendations include: →...
View ArticleNovartis sues Maryland over state law banning limits on discounts to 340B...
Novartis is suing the state of Maryland to block a state law that will ban drugmakers from placing limits on discounts to pharmacies that supply drugs to hospitals serving low-income and uninsured...
View ArticleFDA questions data on MDMA-based therapy in PTSD ahead of advisory committee
The FDA questioned data around Lykos Therapeutics’ MDMA-based therapy for post-traumatic stress disorder on Friday, less than a week before its advisory committee meets to discuss what could be the...
View ArticleClik here to view.
#ASCO24: Immunocore unveils early-stage data of skin cancer treatment that...
CHICAGO — Immunocore reported Friday that in an early-stage study, 56% of melanoma patients who received its experimental drug achieved disease control — a measurement that’s not typically touted by...
View ArticleClik here to view.
Merck CEO says Keytruda is ‘not a repeatable model’
CHICAGO — Can there be another Keytruda? Merck CEO Rob Davis, whose company makes the $25 billion-a-year cancer medicine, says it’s a “once-in-a-lifetime drug” whose success won’t be repeated. “I can...
View ArticleClik here to view.
#ASCO24: Iovance's TIL therapy plus Keytruda show durable treatment effect in...
CHICAGO — Iovance Biotherapeutics said Friday that adding its melanoma cell therapy on top of an immunotherapy — the current go-to for advanced skin cancer — resulted in cancer disappearing in seven...
View ArticleMerck’s $3B return to eye disease; J&J’s $1.25B tuck-in; Keytruda challenger...
Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add...
View ArticleClik here to view.
#ASCO24: BMS details confirmatory trial win for KRAS inhibitor Krazati
Bristol Myers Squibb said its KRAS cancer drug Krazati met the primary endpoint in a Phase 3 confirmatory trial in patients with non-small cell lung cancer, according to new data shared at the American...
View ArticleClik here to view.
#ASCO24: GenFleet highlights Phase 2 data on KRAS/EGFR combo in lung cancer
As companies increasingly look to combinations to boost the efficacy of KRAS therapies, a Phase 2 study is offering some of the first clinical evidence for combining KRAS and EGFR in frontline lung...
View ArticleIntellia’s CRISPR therapy cuts swelling attacks by 98% in two-year study
Intellia Therapeutics has revealed that a single infusion of its experimental CRISPR therapy, called NTLA-2002, almost entirely eliminated swelling attacks in 10 people with hereditary angioedema....
View Article